Drug Profile
Research programme: gastrointestinal disorder therapeutics - Glyph Biosciences/Monash University
Alternative Names: GLY 101Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Glyph Biosciences
- Developer Glyph Biosciences; Monash University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (PO)
- 29 Aug 2017 PureTech in-licenses the Glyph technology from the Monash University
- 29 Aug 2017 Preclinical development in Gastrointestinal disorders in USA (PO) before August 2017